| INTRODUCTION
Hepatitis B virus (HBV) infection is a global health problem and a major cause of cirrhosis, hepatocellular carcinoma (HCC) and liverrelated death. 1 The prevalence of chronic hepatitis B varies widely by geographic region, with the highest rates in Africa and the Western Pacific. 1 The World Health Organization has estimated that 240 million people have chronic hepatitis B, and the Global Burden of Disease Study has identified hepatitis B infection as the tenth leading cause of death in the world, with more than 780 000 deaths per year attributed to this condition. [2] [3] [4] Effective treatment is available for chronic hepatitis B. Contemporary treatment guidelines recommend treatment with either a nucleos(t)ide analogue (Nuc) or an interferon-based therapy with the goal of decreasing chronic hepatitis B-related morbidity and mortality. [5] [6] [7] Elevated alanine aminotransferase (ALT) and HBV DNA levels are strongly associated with an increased risk of liver complications, 8, 9 and anti-viral therapy is associated with reductions in cirrhosis, hepatic decompensation, HCC and death. 5 Nucs profoundly suppress HBV DNA replication, but must be given indefinitely in most patients because of the high rate of relapse after stopping therapy. 5, 6 Indeed, it has been estimated that Nuc treatment would need to be continued for more than 50 years in a typical patient to achieve hepatitis B surface antigen (HBsAg) clearance. 10 Indefinite therapy imposes an ongoing financial burden on healthcare systems and requires consistent long-term adherence from patients. In contrast to Nucs, a finite course of treatment with peginterferon alfa-2a
induces a durable serological response in approximately one-third of patients; 11 and in hepatitis B e antigen (HBeAg)-negative patients, responses to peginterferon alfa-2a have been shown to be maintained for up to 5 years after completion of a standard 48-week course of treatment. 12 The NEPTUNE study investigated the optimal dose and duration of treatment with peginterferon alfa-2a in patients with immuneactive HBeAg-positive disease. The final results of the study showed that HBeAg seroconversion (SC) rates at 6-12 months post-treatment were significantly higher in patients randomised to receive the licensed dosage (180 lg/wk for 48 weeks) when compared with patients randomised to treatment with a lower dose (90 lg/wk) and/or a shorter duration of treatment (24 weeks) (36% vs 14%-16%). 13 The Son of NEPTUNE (SoN) study was designed with the objective of assessing response rates and the relative durability of these responses during long-term follow-up after completion of treatment with peginterferon alfa-2a in the NEPTUNE study.
| ME TH ODS
This was an observational long-term follow-up study of HBeAg-positive patients who had been randomised and received treatment with peginterferon alfa-2a in a large international randomised clinical trial (clinicaltrials.gov NCT00927082). In the parent study (WV19432, clinicaltrials.gov NCT00435825), 13 HBeAg-positive patients were randomised in a 2 9 2 factorial manner to treatment with peginterferon alfa-2a at a dosage of 90 or 180 lg/wk for 24 or 48 weeks in one of four treatment groups (90 lg/wk 9 24 weeks [1] ; 180 lg/ wk 9 24 weeks [2] ; 90 lg/wk 9 48 weeks [3] ; or 180 lg/wk 9 48 weeks [4] ). Patients who completed 24 weeks of post-treatment follow-up in the parent study were eligible for enrolment in this longterm follow-up study regardless of their HBeAg SC status (responder or nonresponder) at end of follow-up in the parent study.
Patients unwilling to provide informed consent or abide by the requirements of the study were excluded. Patients who received treatment with approved or investigational agents for the treatment of chronic hepatitis B were not excluded.
The total duration of post-treatment follow-up within the SoN study was 4 or 4.5 years, depending on the duration of treatment (24 or 48 weeks) in the parent NEPTUNE study. Patients originally randomised to 24 weeks of treatment with peginterferon alfa-2a
had completed 1 year of follow-up prior to entry into this long-term follow-up study, and were followed up for a further 4 years (total duration of follow-up 5 years). Patients originally randomised to 48 weeks of treatment with peginterferon alfa-2a had completed 6 months of follow-up prior to entry into this long-term follow-up study and were followed up for a further 4.5 years (total duration of follow-up 5 years).
| Outcomes
The primary endpoint of the long-term follow-up study was HBeAg SC at each yearly follow-up visit. Secondary endpoints at each yearly follow-up visit included loss of HBeAg, ALT normalisation (in patients with elevated ALT levels at baseline in the parent study), suppression of HBV DNA (<20 000, <2000 and <6 IU/mL), quantitative HBsAg levels, HBsAg loss and SC and combined response, defined as HBeAg SC plus HBV DNA <2000 IU/mL.
Safety was assessed by laboratory investigations, and occurrence of significant clinical sequelae of chronic hepatitis B (including ALT flares [defined as >10 9 ULN], hepatic decompensation, HCC, hepatic decompensation and liver transplantation).
| Statistical analysis
A total of 551 patients were randomised and 548 of the 551 patients received at least one dose of study medication and comprised the intent-to-treat population in the parent study ( Figure 1 ).
The per-protocol population of the parent study comprised 544 patients and included patients who met the inclusion and exclusion criteria and received at least 4 weeks of treatment with study drug.
In addition, patients in the per-protocol population were analysed according to the actual duration of treatment received. Thus, patients who received ≤28 weeks of treatment were included in a 24-week treatment group (1 or 2, depending on the dose of peginterferon alfa-2a received), while those who received >28 weeks of treatment were included in a 48-week treatment group (3 or 4, depending on the dose of peginterferon alfa-2a received). All Table S1 .
Baseline demographic and disease characteristics are shown in Figure 3B ). Moreover, the odds ratio for HBeAg SC in group 4 vs groups 1-3 combined was 2.06 (CI 1.25, 3.37).
Durable and delayed response rates were also examined in post hoc analyses ( 
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ALT, alanine aminotransferase; SD, standard deviation; ULN, upper limit of normal for the local laboratory.
was similar to that in group 3 (28.6%), but higher than in group 1 (7.1%) or 2 (5.2%).
| Prediction of treatment response

MLR analysis of baseline factors in patients enrolled in group 4
showed that HBeAg SC after 5 years of follow-up was associated with a low HBV DNA level (< 25 vs ≥ 25 9 10 6 IU/mL, OR 2. Four patients, all of whom had received the lower dose of peginterferon alfa-2a, were diagnosed with HCC, and four patients experienced hepatic decompensation during follow-up (Table S3) .
One patient died during follow-up. This 59-year-old woman in group 3 (48 weeks' treatment, 90 lg/wk) had previously been diagnosed with cirrhosis, diabetes mellitus and chronic renal insufficiency. She experienced hepatic decompensation (increased ascites) on study day 1 and died of unknown cause on study day 214. The 
| DISCUSSION
The results of this prospective, long-term follow-up study confirm that response rates continue to increase for up to 5 years after completion of treatment with peginterferon alfa-2a in HBeAg-positive patients.
These results are consistent with those in HBeAg-negative patients treated with peginterferon alfa-2a. 12 After 5 years of follow-up in the present study, the highest rates of HBeAg SC and combined responses were achieved in patients who were treated with the licensed dosage regimen (180 lg/wk for 48 weeks) than with a lower dose (90 lg/wk) and/or a shorter duration (24 weeks), although the between-group differences are smaller than those observed in NEPTUNE. When patients with missing values were excluded, and patients who received Nuc/IMs were considered to be nonresponders, the response rates across the four treatment groups more closely resembled those at the end of follow-up in the parent study, with a clearly higher response rate in patients who received the licensed dosage regimen (39% in group 4, versus 23.5% to 32.1% in groups 1-3).
When multiple imputation methods were used to estimate HBeAg T A B L E 2 Virological outcomes after 5 years of follow-up. Patients with missing data were considered to be nonresponders for each endpoint Outcome, n (%) The results extend knowledge of the prediction of response using on-treatment HBsAg levels. [15] [16] [17] [18] Sonneveld et al 16 conducted a genotype-specific analysis of data from three clinical trials and showed that, in patients with HBsAg levels < 1500, 1500-20 000
and > 20 000 IU/mL at week 12, combined response rates (HBeAg SC plus HBV DNA < 2000 IU/mL) after 6 months' follow-up were 42%, 26% and 8% in genotype B patients and 42%, 20% and 2% in genotype C patients. The results of our analysis are consistent with those of Sonneveld et al 15, 16 and show that on-treatment prediction of response applies to longer durations of follow-up. Among patients in group 4 (48 weeks' treatment, 180 lg/week) with HBsAg levels of <1500, 1500-<20 000 and ≥ 20 000 IU/mL at week 12, HBeAg SC rates after 5 years' follow-up were 66.7%, 49.1% and 7.1%, respectively. Of note, response rates were consistently lower in patients in groups 1-3 with HBsAg levels <1500 IU/mL at week 12 of treatment than in patients with similar levels in group 4, which suggests that the standard prediction rule applies best to patients treated with the licensed regimen. On the basis of the analyses of T A B L E 3 HBeAg seroconversion rates at end of treatment, follow-up week 24 and follow-up year 5 in patients included in the long-term follow-up study. Durable and delayed HBeAg seroconversion rates are also shown Only patients with available HBsAg data are included in calculations.
Patients without follow-up data are considered to be nonresponders.
Sonneveld et al, 15, 16 EASL guidelines recommend that treatment with peginterferon be stopped in HBeAg-positive patients who fail to achieve HBsAg < 20 000 IU/mL (or any decline in serum HBsAg)
at week 12 of treatment because of the low chance of HBeAg SC. 6 The results of this study provide an opportunity to evaluate the long-term sequelae of chronic hepatitis B after treatment with peginterferon alfa-2a. Over 5 years of follow-up, approximately 6% of patients experienced ALT flares, defined as > 10 9 ULN. HBeAg SC rates were somewhat higher in patients with than without ALT flares, which is consistent with a previous report that flares during treatment with peginterferon alfa are often associated with HBeAg SC. 19 The incidence of HCC and hepatic decompensation was low over 5 years of follow-up. Of note, HCC was not detected in any patient who received the licensed dose of peginterferon alfa-2a
(180 lg/wk); however, the numbers are too small to determine whether this is a clinically meaningful result.
This study has certain aspects that limit the strength of the conclusions. Not all patients who were randomised to treatment in the original trial were enrolled in the long-term follow-up study; and of those who were enrolled, not all returned for follow-up after (180 lg 9 48 weeks) is more efficacious for HBeAg-positive patients than regimens that include a lower dose or shorter duration.
